Semaglutide
STEP 1
Novo Nordisk · Phase 3 · Completed · Enrollment 1961
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide s.c. 2.4 mg once weekly | 83.5% | n/r | n/r | n/r |
| Semaglutide placebo | 31.1% | n/r | n/r | n/r |
Not shown
Every selected arm is drawn.